MBS307 / Beijing Mabworks Biotech - LARVOL DELTA

Preclinical characterization of MBS307, a CD40/PD-L1 trispecific antibody with increased therapeutic window and efficacy (AACR 2023) - "Furthermore, unlike single CD40 mAB treatment at 10 mg/kg, MBS307 at high dose 15 mg/kg did not elevate liver enzymes and decrease mouse body weight, indicating its improved safety profile. In summary, our data show MBS307 is a functional base designed tri-specific antibody with promising anti-tumor efficacy and safety profile by simultaneously blocking PD-1 and stimulating CD40 pathways."

IO biomarker • Preclinical • Trispecific • Oncology • CD24 • CD40 • TNFA